Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study-Reference-Cited by-同舟云学术

Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study

Published:2021-08-05 Issue:9 Volume:51 Page:943-956
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Okanoue Takeshi¹,Sakamoto Michiie²,Harada Kenichi³,Inagaki Masaya⁴,Totsuka Naoko⁵,Hashimoto Gaia⁵,Kumada Hiromitsu⁶

Affiliation:

1. Department of Gastroenterology Saiseikai Suita Hospital Osaka Japan

2. Department of Pathology Keio University School of Medicine Tokyo Japan

3. Department of Human Pathology Kanazawa University Graduate School of Medicine Kanazawa Japan

4. Data Science Department Ikuyaku, Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan

5. Clinical Research and Development II Department Ikuyaku, Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan

6. Department of Hepatology Toranomon Hospital Tokyo Japan

Funder

Mitsubishi Tanabe Pharma Corporation

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13695

Reference39 articles.

1. Evidence‐based clinical practice guidelines for non‐alcoholic fatty liver disease/nonalcoholic steatohepatitis, Japanese Guideline 2020;The Japanese Society of Gastroenterology, the Japan Society of Hepatology,2020

2. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study

3. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) 2018 Guidance for Industry

4. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

5. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Options for patients with out-of-control blood pressure: after all avenues have been exhausted;Expert Review of Cardiovascular Therapy;2024-09-11

2. Decoding the role of aldosterone in glycation-induced diabetic complications;Biochemical and Biophysical Research Communications;2024-08

3. Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease;Pharmaceuticals;2024-03-26

4. Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis;Metabolism Open;2024-03

5. Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis;Biochemical Pharmacology;2024-02